Patents by Inventor Liusheng Zhu

Liusheng Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210230189
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: July 29, 2021
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, David Karl BEDKE, Micheal R. DEGRAFFENREID, Jiasheng FU, Zhihong LI, Felix GONZALEZ LOPEZ TURISO, Ana GONZALEZ BUENROSTRO, Micheal W. GRIBBLE, JR., Micheal G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcal WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Marlo G. CARDOZO, Alan C. CHENG
  • Publication number: 20210214387
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 15, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Patent number: 11028120
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: June 8, 2021
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • Publication number: 20210130390
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: December 8, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Publication number: 20210130389
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 6, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • Publication number: 20210122730
    Abstract: Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 29, 2021
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Yosup REW, Daqing SUN, Qiuping YE, Haiying ZHOU, Hiroyuki KAWAI, Jared MOORE, Johnny PHAM, Kejia WU, Liusheng ZHU, Dennis YAMASHITA
  • Publication number: 20210047359
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 18, 2021
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • Publication number: 20210023095
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 28, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Publication number: 20210017220
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Publication number: 20210017219
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 21, 2021
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Publication number: 20210002324
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
    Type: Application
    Filed: December 22, 2016
    Publication date: January 7, 2021
    Inventors: Daqing SUN, Lawrence R. MCGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Haiying ZHOU, Minna Delarae BALBAS, Valeria R. FANTIN
  • Patent number: 10836779
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • Patent number: 10836789
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: November 17, 2020
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Publication number: 20200291058
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Patent number: 10723759
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: July 28, 2020
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
  • Publication number: 20200062780
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 27, 2020
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20200055892
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 20, 2020
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Patent number: 10472387
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 12, 2019
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina
  • Publication number: 20190218246
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: March 26, 2019
    Publication date: July 18, 2019
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • Publication number: 20190023720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI